RNS Number : 1007X
  Lipoxen PLC
  19 June 2008
   

    Lipoxen PLC
    ("Lipoxen" or "the Company")

    Clarification of the announcement that Lipoxen has received approval to conduct the second Phase I trial of its long-acting
erythropoietin (EPO), ErepoXen�, in Canada, released at 
    07.00 a.m. on 16 June 2008 under RNS number 7369W  
    
    

    London, UK, 19 June 2008 - Lipoxen PLC (AIM:LPX), a bio-pharmaceutical company specialising in the development of high value
differentiated biologicals, vaccines and oncology drugs wishes to clarify that, although Institutional Review Board (IRB) ethical approval
has been granted for the Phase I erythropoietin (EPO) trial in Canada, further regulatory approval is needed before the trial can proceed to
dosing. 

    A further announcement will be made when full trial approval is granted.

    - ENDS -

    Enquiries 
 Lipoxen PLC
 M. Scott Maguire, Chief Executive Officer               +44 (0)20 7691 3583 

 Landsbanki Securities (UK) Limited (nominated adviser)
 Shaun Dobson / Claes Spg                                +44 (0)20 7426 9000

 Citigate Dewe Rogerson
 David Dible / Heather Keohane                           +44 (0)20 7638 9571




    Notes to Editors

    Further information on Lipoxen Lipoxen PLC (AIM:LPX) is a biopharmaceutical company specializing in the development of high value
differentiated biologicals, vaccines and oncology drugs. Products currently under development include improved formulations of important
biologicals such as erythropoietin (EPO), G-CSF, insulin and Interferon-alpha. Lipoxen has two products in clinical development SuliXen, a
long-acting human insulin and ErepoXen�, long-acting EPO. These novel products, which are based on Lipoxen's proprietary PolyXen�
technology, each address markets in excess of US$1 billion. Lipoxen's technology is designed to improve the stability, biological half-life
and immunologic characteristics of therapeutic proteins naturally. Lipoxen has two further naturally-derived proprietary delivery
technologies, ImuXen� and a related liposomal technology for the formulation of cytotoxic oncology drugs, which are being developed to
enhance the efficacy and safety of various vaccines such as a multivalent Hepatitis B-E and pneumococcal vaccines, as well as a number of anti-cancer agents like paclitaxel. The Company's proprietary delivery
technologies are attracting significant interest and Lipoxen is currently co-developing products with the Serum Institute of India Limited
(one of the world's leading vaccine companies, India's largest biotech company and a major shareholder in Lipoxen) and has license
agreements in place with Baxter International and InterVet, a leading animal health company.Lipoxen was admitted to trading on the AIM
Market of the London Stock Exchange in January 2006.

    This announcement includes 'forward-looking statements' which include all statements other than statements of historical facts,
including, without limitation, those regarding the Company's financial position, business strategy, plans and objectives of management for
future operations (including development plans and objectives relating to the Company's products and services), and any statements preceded
by, followed by or that include forward-looking terminology such as the words 'targets', 'believes', 'estimates', 'expects', 'aims',
'intends', 'will', 'can', 'may', 'anticipates', 'would', 'should', 'could' or similar expressions or the negative thereof. Such
forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control that
could cause the actual results, performance or achievements of the Company to be materially different from future results, performance or
achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the
environment in which the Company will operate in the future. Among the important factors that could cause the Company's actual results,
performance or achievements to differ materially from those in forward-looking statements include those relating to The Company's funding
requirements, regulatory approvals, clinical trials, reliance on third parties, intellectual property, key personnel and other factors.
These forward-looking statements speak only as at the date of this announcement. The Company expressly disclaims any obligation or
undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change
in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are
based. As a result of these factors, readers are cautioned not to rely on any forward-looking statement

This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
RESFLMBTMMABBMP
Lipoxen (LSE:LPX)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Lipoxen Charts.
Lipoxen (LSE:LPX)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Lipoxen Charts.